Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Scienture
Deal Size : Undisclosed
Deal Type : Agreement
Scienture, Kindeva Launch REZENOPY® for Opioid Overdose Treatment
Details : Under the agreement, Scienture will own the NDA for Rezenopy (Naloxone HCl) in its name and be responsible for the sales, marketing and distribution of the product in the US.
Product Name : Rezenopy
Product Type : Controlled Substance
Upfront Cash : Undisclosed
March 06, 2025
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Scienture
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Ridinilazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Polar Capital
Deal Size : $50.0 million
Deal Type : Private Placement
Summit Announces Closing of Private Placement of $50 Million
Details : Funds to be used for continued patient enrolment into the Ri-CoDIFy Phase 3 clinical trial program of ridinilazole; Preparatory activities to support the commercial launch of ridinilazole; Development of early-stage research projects using Discuva Platfo...
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Undisclosed
November 06, 2020
Lead Product(s) : Ridinilazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Polar Capital
Deal Size : $50.0 million
Deal Type : Private Placement
Reset All
